Endicott David J. 4
4 · Orexigen Therapeutics, Inc. · Filed Jul 18, 2017
Insider Transaction Report
Form 4
Endicott David J.
Director
Transactions
- Award
Stock Option (Right to Buy)
2017-07-14+5,000→ 5,000 totalExercise: $2.88Exp: 2027-07-13→ Common Stock (5,000 underlying)
Footnotes (1)
- [F1]1/12th of the original number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following the vesting commencement date of July 14, 2017, subject to the Reporting Person's continuing service on the Issuer's Board of Directors through each such date, and subject to the terms of the Stock Option Agreement in the event of a change in control of the Issuer.